ACG Clinical Guideline: Hepatic Encephalopathy

Jasmohan S Bajaj1, Sofia S Jakab2, Arun B Jesudian3

  • 1Virginia Commonwealth University and Richmond VA Medical Center, Richmond, Virginia, USA.

Insights

Hepatic encephalopathy (HE) significantly impacts cirrhosis patients, often leading to inadequate transplant prioritization. This guideline offers 24 evidence-based recommendations for HE diagnosis, management, and prevention.

Area of Science:

  • Gastroenterology
  • Hepatology
  • Clinical Practice Guidelines

Background:

  • Hepatic encephalopathy (HE) is a serious complication of cirrhosis, affecting patients, families, and healthcare systems.
  • Current liver transplant criteria may not adequately reflect HE progression and its impact on quality of life.
  • This highlights a gap in prioritizing patients for transplantation despite significant functional impairment.

Purpose of the Study:

  • To provide comprehensive, evidence-based recommendations for the diagnosis of hepatic encephalopathy.
  • To outline effective management strategies for patients with hepatic encephalopathy.
  • To present guidelines for the prevention of hepatic encephalopathy in cirrhosis patients.

Main Methods:

  • Development of 24 recommendations based on the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework.
  • Systematic review and appraisal of evidence quality for each recommendation.
  • Inclusion of key concepts for statements not assessed by the GRADE process.

Main Results:

  • The guideline presents 24 distinct recommendations covering diagnosis, management, and prevention of hepatic encephalopathy.
  • Evidence quality was rigorously assessed using the GRADE methodology.
  • Key concepts are provided to supplement the GRADE-assessed statements.

Conclusions:

  • Hepatic encephalopathy requires a structured approach to diagnosis, management, and prevention in cirrhosis.
  • The guideline aims to improve patient care and potentially inform transplant prioritization.
  • Adherence to these recommendations can mitigate the burden of hepatic encephalopathy.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...